Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
USD 90.61
(0.0%)
USD 90.61
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 245.4 Million EUR | -12.17% |
| 2022 | 281.44 Million EUR | 37.96% |
| 2021 | 202.68 Million EUR | 109.46% |
| 2020 | 92.98 Million EUR | 58.83% |
| 2019 | 60.74 Million EUR | 106.82% |
| 2018 | 29.43 Million EUR | -1.85% |
| 2017 | 30.01 Million EUR | -24.63% |
| 2016 | 39.82 Million EUR | 21.95% |
| 2015 | 32.65 Million EUR | -12.03% |
| 2014 | 36.81 Million EUR | 13.44% |
| 2013 | 32.68 Million EUR | 18.4% |
| 2012 | 28.33 Million EUR | 6.6% |
| 2011 | 26.01 Million EUR | -16.58% |
| 2010 | 31.05 Million EUR | 16.17% |
| 2009 | 28.4 Million EUR | -14.34% |
| 2008 | 22.52 Million EUR | 86.06% |
| 2007 | 16.78 Million EUR | 554.68% |
| 2006 | 2.56 Million EUR | -100.0% |
| 2005 | 421.53 Billion EUR | 24321.68% |
| 2004 | 1.72 Billion EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 44.28 Million EUR | 72.06% |
| 2024 Q1 | 25.88 Million EUR | -64.65% |
| 2023 Q4 | 73.12 Million EUR | -1.83% |
| 2023 Q2 | 31.07 Million EUR | -53.56% |
| 2023 FY | - EUR | -12.17% |
| 2023 Q3 | 74.48 Million EUR | 139.68% |
| 2023 Q1 | 66.91 Million EUR | -37.27% |
| 2022 Q4 | 106.67 Million EUR | 86.73% |
| 2022 Q1 | 74.3 Million EUR | 17.56% |
| 2022 FY | - EUR | 37.96% |
| 2022 Q3 | 57.13 Million EUR | 37.63% |
| 2022 Q2 | 41.51 Million EUR | -44.14% |
| 2021 Q4 | 63.21 Million EUR | -3.41% |
| 2021 Q1 | 34.77 Million EUR | 28.87% |
| 2021 Q2 | 39.26 Million EUR | 12.91% |
| 2021 Q3 | 65.44 Million EUR | 66.69% |
| 2021 FY | - EUR | 109.46% |
| 2020 FY | - EUR | 58.83% |
| 2020 Q1 | 20.08 Million EUR | 49.85% |
| 2020 Q4 | 26.98 Million EUR | -1.35% |
| 2020 Q2 | 22.35 Million EUR | 11.3% |
| 2020 Q3 | 27.35 Million EUR | 22.37% |
| 2019 Q1 | 11.97 Million EUR | 245.36% |
| 2019 Q2 | 14.52 Million EUR | 21.23% |
| 2019 FY | - EUR | 106.82% |
| 2019 Q4 | 13.4 Million EUR | -36.27% |
| 2019 Q3 | 21.02 Million EUR | 44.82% |
| 2018 Q4 | 3.46 Million EUR | -72.57% |
| 2018 FY | - EUR | -1.85% |
| 2018 Q3 | 12.64 Million EUR | 300.28% |
| 2018 Q2 | 3.15 Million EUR | -68.92% |
| 2018 Q1 | 10.16 Million EUR | 242.11% |
| 2017 Q2 | 13.53 Million EUR | 33.14% |
| 2017 Q1 | 10.16 Million EUR | 23.48% |
| 2017 FY | - EUR | -24.63% |
| 2017 Q4 | 2.97 Million EUR | -11.23% |
| 2017 Q3 | 3.34 Million EUR | -75.27% |
| 2016 Q3 | 6.4 Million EUR | -46.92% |
| 2016 Q2 | 12.06 Million EUR | -8.09% |
| 2016 FY | - EUR | 21.95% |
| 2016 Q4 | 8.23 Million EUR | 28.55% |
| 2016 Q1 | 13.12 Million EUR | 94.69% |
| 2015 Q3 | 6.03 Million EUR | -40.86% |
| 2015 Q1 | 9.67 Million EUR | 30.93% |
| 2015 FY | - EUR | -12.03% |
| 2015 Q4 | 6.74 Million EUR | 11.7% |
| 2015 Q2 | 10.2 Million EUR | 5.5% |
| 2014 Q1 | 9.16 Million EUR | 31.2% |
| 2014 FY | - EUR | 13.44% |
| 2014 Q3 | 8.13 Million EUR | -33.03% |
| 2014 Q4 | 7.38 Million EUR | -9.13% |
| 2014 Q2 | 12.13 Million EUR | 32.49% |
| 2013 Q2 | 10.93 Million EUR | 42.08% |
| 2013 Q3 | 7.07 Million EUR | -35.27% |
| 2013 Q4 | 6.98 Million EUR | -1.3% |
| 2013 FY | - EUR | 18.4% |
| 2013 Q1 | 7.69 Million EUR | -30.86% |
| 2012 Q2 | 9.89 Million EUR | 40.62% |
| 2012 FY | - EUR | 6.6% |
| 2012 Q3 | 5.64 Million EUR | -42.93% |
| 2012 Q4 | 11.12 Million EUR | 97.02% |
| 2012 Q1 | 7.03 Million EUR | -37.06% |
| 2011 Q2 | 10.43 Million EUR | 59.71% |
| 2011 Q3 | 4.84 Million EUR | -53.58% |
| 2011 FY | - EUR | -16.58% |
| 2011 Q4 | 11.17 Million EUR | 130.82% |
| 2011 Q1 | 6.53 Million EUR | 1058.16% |
| 2010 Q4 | 564 Thousand EUR | -92.9% |
| 2010 Q1 | 7.13 Million EUR | 0.0% |
| 2010 Q2 | 15.43 Million EUR | 116.24% |
| 2010 FY | - EUR | 16.17% |
| 2010 Q3 | 7.94 Million EUR | -48.53% |
| 2009 FY | - EUR | -14.34% |
| 2008 FY | - EUR | 86.06% |
| 2007 FY | - EUR | 554.68% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | - EUR | 24321.68% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.06 Million USD | 8111.907% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 7018.696% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 10842.271% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 1512.815% |
| GB Sciences, Inc. | -1.41 Million USD | 17383.512% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -64677.587% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 2006854.436% |
| Skye Bioscience, Inc. | -13.54 Million USD | 1911.442% |
| Zenith Capital Corp. | -8.6 Million USD | 2951.569% |
| Agentix Corp. | -1.37 Million USD | 17989.916% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 6417.863% |
| Biomind Labs Inc. | -1.03 Million USD | 23821.061% |
| ContraFect Corporation | -64.99 Million USD | 477.554% |
| CSL Limited | 4.78 Billion USD | 94.876% |
| CytoDyn Inc. | -18.02 Million USD | 1461.174% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -3649602.558% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 38905.135% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 543.459% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 66927.877% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 16076.443% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 26292.034% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -160.964% |
| SQZ Biotechnologies Company | -64.14 Million USD | 482.604% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 16598.858% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 445.467% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 9380.046% |
| Mesoblast Limited | -62.38 Million USD | 493.343% |
| Marizyme, Inc. | -34.28 Million USD | 815.856% |
| Genus plc | 73.7 Million USD | -232.98% |
| Pharming Group N.V. | 9.87 Million USD | -2384.621% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 2897.606% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 17606.392% |
| IMV Inc. | -35.52 Million USD | 790.829% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 10660.456% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 47471.469% |
| ONE Bio Corp. | 13.61 Million USD | -1702.727% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 608.856% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -6770.269% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 8584.728% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 3526.848% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 981724.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1646.377% |
| Alpha Cognition Inc. | -9.7 Million USD | 2628.499% |
| Enzolytics Inc. | -2.12 Million USD | 11664.686% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -216.02 Million USD | 213.602% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -20064.832% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -2671.759% |
| Genscript Biotech Corporation | -248.71 Million USD | 198.668% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 4239.143% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 102715.931% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 10131.061% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 139515.931% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 12875.501% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 3811.796% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 5521.905% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 6650.415% |
| Helix BioMedix, Inc. | -1.04 Million USD | 23554.381% |
| EV Biologics, Inc. | -1.26 Million USD | 19467.043% |
| Q BioMed Inc. | -617.62 Thousand USD | 39833.626% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 14123.208% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 719.136% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 3348.842% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 9908.542% |
| HST Global, Inc. | -5303.00 USD | 4627782.444% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 12030.287% |
| Halberd Corporation | -74.27 Thousand USD | 330484.092% |
| Resverlogix Corp. | -11.74 Million USD | 2189.985% |
| Cell Source, Inc. | -4.27 Million USD | 5843.815% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 16472.341% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | -6.11 Million USD | 4114.728% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1408779.18% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | 23815.376% |
| Kadimastem Ltd | -2.62 Million USD | 9451.005% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 64745.171% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 135617.538% |
| LadRx Corporation | 412.28 Thousand USD | -59423.677% |
| Regen BioPharma, Inc. | 1.46 Million USD | -16640.339% |
| Affymax, Inc. | -14.29 Million USD | 1816.726% |
| Itoco Inc. | -1.86 Million USD | 13230.372% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 22089.785% |
| Mobile Lads Corp. | -2.24 Million USD | 11049.959% |
| International Stem Cell Corporation | 202 Thousand USD | -121388.119% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 6523.994% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 310626.516% |
| Qrons Inc. | -40.08 Thousand USD | 612375.143% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 50628.539% |
| SYBLEU INC | -141.57 Thousand USD | 173444.823% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -46428.374% |
| Rebus Holdings, Inc. | -951 Thousand USD | 25905.047% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 23207.692% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 466296.809% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 10068.025% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 784.173% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 545446.667% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 9062.966% |
| Neutra Corp. | -181.24 Thousand USD | 135498.655% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1317.352% |
| PureTech Health plc | -11.62 Million USD | 2210.656% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 1317.436% |
| IXICO plc | -707 Thousand USD | 34810.891% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 3293.312% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 607.604% |
| CSL Limited | 4.73 Billion USD | 94.815% |
| Cellectis S.A. | -92.63 Million USD | 364.914% |